risperidone has been researched along with Acute Post-Traumatic Stress Disorder in 32 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study tested the hypothesis that low-dose risperidone reduces aggression and other PTSD-related symptoms in combat veterans." | 9.10 | Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. ( Ciraulo, DA; Keane, T; Knapp, C; Monnelly, EP, 2003) |
| " This study tested the hypothesis that low-dose risperidone reduces aggression and other PTSD-related symptoms in combat veterans." | 5.10 | Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. ( Ciraulo, DA; Keane, T; Knapp, C; Monnelly, EP, 2003) |
| "DSM-IV PTSD diagnoses were made by using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Nonpatient Edition." | 2.82 | Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504. ( Collins, J; Cramer, JA; Huang, GD; Jones, KM; Krystal, AD; Krystal, JH; Pietrzak, RH; Rosenheck, RA; Vertrees, JE; Vessicchio, J, 2016) |
| "T-tests showed that the PTSD sample had more severe symptoms on the Depressive factor, and the schizophrenia sample on the Positive, Negative, and Disorganized factors, with no significant difference on the Excited factor." | 2.79 | Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia. ( Krystal, JH; Rosenheck, RA; Stefanovics, EA, 2014) |
| "The Clinician-Administered PTSD Scale (CAPS) (range, 0-136)." | 2.76 | Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. ( Cramer, JA; Horney, RA; Huang, GD; Jones, KM; Krystal, JH; Rosenheck, RA; Stock, C; Vertrees, JE; Vessicchio, JC, 2011) |
| "Symptoms of PTSD and depression and psychotic symptoms were measured prospectively throughout the 16-week study." | 2.73 | Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. ( Brady, KT; Connor, KM; Davidson, JR; Heekin, MH; Killeen, TK; Rothbaum, BO, 2008) |
| "Risperidone was well tolerated with minimal extrapyramidal symptoms." | 2.71 | Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. ( Arana, GW; Faldowski, RA; Frueh, BC; Hamner, MB; Huber, MG; Ulmer, HG, 2003) |
| "Risperidone-treated patients had a significantly greater reduction in total score on the CAPS-2 (z = -2." | 2.71 | A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. ( Hennen, J; Reich, DB; Stanculescu, C; Watts, T; Winternitz, S, 2004) |
| "Risperidone was added to a stable psychotropic medication regimen in 92% of subjects." | 2.71 | Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. ( Bartzokis, G; Lu, PH; Mintz, J; Saunders, CS; Turner, J, 2005) |
| "Treatment with risperidone for either 3 or 6 weeks in an open trial significantly reduced total and subscales scores on the PANSS and on the PTSD-I and CGI-S when compared to baseline scores in patients with psychotic PTSD." | 2.71 | Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. ( Kozarić-Kovacić, D; Mück-Seler, D; Pivac, N; Rothbaum, BO, 2005) |
| "Posttraumatic stress disorder (PTSD) is an important mental health issue in terms of the number of people affected and the morbidity and functional impairment associated with the disorder." | 2.49 | Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. ( Friedman, MJ; Mayo, L; Schnurr, PP; Watts, BV; Weeks, WB; Young-Xu, Y, 2013) |
| "Posttraumatic stress disorder (PTSD) can be a chronic and disabling illness with a limited response to antidepressant treatment, particularly in the case of combat-induced PTSD." | 2.47 | A review of atypical antipsychotic medications for posttraumatic stress disorder. ( Ahearn, EP; Becker, T; Cordes, T; Juergens, T; Krahn, D, 2011) |
| "Posttraumatic stress disorder (PTSD) is a prevalent and disabling mental illness." | 2.44 | The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. ( Ajwani, N; Lee, C; Lim, HK; Pae, CU; Patkar, AA; Peindl, K; Serretti, A, 2008) |
| "Risperidone and piracetam were found to be effective alone, while their high dose combination, produced potentiating effect in reversing the extinction deficit, behavioral alterations, altered cortical and hippocampal BDNF, IL-6, TNF-α, caspase-3, oxidative stress markers, and neurotransmitter levels." | 1.51 | Co-treatment of piracetam with risperidone rescued extinction deficits in experimental paradigms of post-traumatic stress disorder by restoring the physiological alterations in cortex and hippocampus. ( Akhtar, A; Bansal, Y; Kuhad, A; Sah, SP; Singh, R; Uniyal, A, 2019) |
| "Posttraumatic stress disorder (PTSD) is a chronic and often difficult-to-treat condition that is prevalent among military veterans." | 1.46 | Correlates of Nonimprovement to Pharmacotherapy for Chronic, Antidepressant-Resistant, Military Service-Related Posttraumatic Stress Disorder: Insights From the Veterans Affairs Cooperative Study No. 504. ( Byrne, SP; Krystal, JH; Pietrzak, RH; Rosenheck, RA; Vessicchio, J, 2017) |
| "Risperidone ameliorated increase in the activity of mitochondrial respiratory complex (I, II, IV, and V), decreases in the levels of mitochondrial membrane potential, cytochrome-C and caspase-9 in the hippocampus, hypothalamus, pre-frontal cortex, and amygdala." | 1.42 | Risperidone Attenuates Modified Stress-Re-stress Paradigm-Induced Mitochondrial Dysfunction and Apoptosis in Rats Exhibiting Post-traumatic Stress Disorder-Like Symptoms. ( Ahmad, A; Garabadu, D; Krishnamurthy, S, 2015) |
| "The management for post-traumatic stress disorder (PTSD) involves chronic administration of drugs." | 1.39 | Risperidone ameliorates post-traumatic stress disorder-like symptoms in modified stress re-stress model. ( Garabadu, D; Joy, KP; Krishnamurthy, S, 2013) |
| "PTSD is a possible sequela of exposure to traumatic events." | 1.30 | Risperidone as an adjunct therapy for post-traumatic stress disorder. ( Krashin, D; Oates, EW, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (12.50) | 18.2507 |
| 2000's | 13 (40.63) | 29.6817 |
| 2010's | 13 (40.63) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Rosenheck, R | 1 |
| Kurtz, SG | 1 |
| Anand, ST | 1 |
| Hau, C | 1 |
| Smedberg, D | 1 |
| Sicilia, R | 1 |
| Pontzer, JF | 1 |
| Ferguson, RE | 1 |
| Uniyal, A | 1 |
| Singh, R | 1 |
| Akhtar, A | 1 |
| Bansal, Y | 1 |
| Kuhad, A | 1 |
| Sah, SP | 1 |
| Jerrom, R | 1 |
| Mortimer, H | 1 |
| Martin, K | 1 |
| Siddiquee, R | 1 |
| Bagchi, D | 1 |
| Goulding, JMR | 1 |
| Byrne, SP | 1 |
| Krystal, JH | 5 |
| Rosenheck, RA | 5 |
| Vessicchio, J | 2 |
| Pietrzak, RH | 3 |
| Watts, BV | 1 |
| Schnurr, PP | 1 |
| Mayo, L | 1 |
| Young-Xu, Y | 1 |
| Weeks, WB | 1 |
| Friedman, MJ | 1 |
| Krishnamurthy, S | 2 |
| Garabadu, D | 2 |
| Joy, KP | 1 |
| Cukor, J | 1 |
| Difede, J | 1 |
| Stefanovics, EA | 1 |
| Cramer, JA | 3 |
| Vessichio, JC | 1 |
| Tsai, J | 1 |
| Southwick, SM | 1 |
| Ahmad, A | 1 |
| Jones, KM | 2 |
| Huang, GD | 2 |
| Vertrees, JE | 2 |
| Collins, J | 1 |
| Krystal, AD | 1 |
| Keeshin, BR | 1 |
| Strawn, JR | 1 |
| Khachiyants, N | 2 |
| Ali, R | 2 |
| Kovesdy, CP | 1 |
| Detweiler, JG | 2 |
| Kim, KY | 2 |
| Detweiler, MB | 2 |
| Ahearn, EP | 1 |
| Juergens, T | 1 |
| Cordes, T | 1 |
| Becker, T | 1 |
| Krahn, D | 1 |
| Vessicchio, JC | 1 |
| Horney, RA | 1 |
| Stock, C | 1 |
| Hamner, MB | 1 |
| Faldowski, RA | 1 |
| Ulmer, HG | 1 |
| Frueh, BC | 1 |
| Huber, MG | 1 |
| Arana, GW | 1 |
| Monnelly, EP | 1 |
| Ciraulo, DA | 1 |
| Knapp, C | 1 |
| Keane, T | 1 |
| Reich, DB | 1 |
| Winternitz, S | 1 |
| Hennen, J | 1 |
| Watts, T | 1 |
| Stanculescu, C | 1 |
| Bartzokis, G | 1 |
| Lu, PH | 1 |
| Turner, J | 1 |
| Mintz, J | 1 |
| Saunders, CS | 1 |
| Kozarić-Kovacić, D | 1 |
| Pivac, N | 1 |
| Mück-Seler, D | 1 |
| Rothbaum, BO | 2 |
| Rasmussen, K | 1 |
| Padala, PR | 1 |
| Madison, J | 1 |
| Monnahan, M | 1 |
| Marcil, W | 1 |
| Price, P | 1 |
| Ramaswamy, S | 1 |
| Din, AU | 1 |
| Wilson, DR | 1 |
| Petty, F | 1 |
| Stevens, HE | 1 |
| Pae, CU | 1 |
| Lim, HK | 1 |
| Peindl, K | 1 |
| Ajwani, N | 1 |
| Serretti, A | 1 |
| Patkar, AA | 1 |
| Lee, C | 1 |
| Berger, W | 1 |
| Portella, CM | 1 |
| Fontenelle, LF | 1 |
| Kinrys, G | 1 |
| Mendlowicz, MV | 1 |
| Killeen, TK | 1 |
| Davidson, JR | 1 |
| Brady, KT | 1 |
| Connor, KM | 1 |
| Heekin, MH | 1 |
| Feeney, DJ | 1 |
| Klykylo, W | 1 |
| Leyba, CM | 1 |
| Wampler, TP | 1 |
| Roberts, MD | 1 |
| Krashin, D | 1 |
| Oates, EW | 1 |
| Eidelman, I | 1 |
| Seedat, S | 1 |
| Stein, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Stellate Ganglion Block to Augment Trauma-focused Therapy Among Veterans With PTSD[NCT05107752] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-01-03 | Recruiting | ||
| Co-occurring Eating Disorders and Posttraumatic Stress Disorder: Facilitating Full and Sustained Recovery Through Empirically-Based Concurrent Treatment[NCT03502564] | 43 participants (Actual) | Interventional | 2015-10-22 | Completed | |||
| Wearable Emotion Prosthetics for Post Traumatic Stress Disorder[NCT03529981] | 16 participants (Actual) | Interventional | 2018-04-09 | Completed | |||
| Acupuncture and Meditation for Wellness (AMWELL)[NCT04859686] | 77 participants (Actual) | Interventional | 2008-09-01 | Completed | |||
| Effectiveness of Thought Field Therapy Provided by Newly Instructed Community Workers to a Traumatized Population in Uganda: A Randomised Trial[NCT01681628] | 256 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| CSP #504 - Risperidone Treatment for Military Service Related Chronic Post-Traumatic Stress Disorder[NCT00099983] | Phase 2 | 296 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Double-Blind, Placebo-Controlled Random Order Crossover Study of Iloperidone for Symptoms of Arousal in PTSD Including Insomnia and Irritability.[NCT01917318] | Phase 2 | 1 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to Enrollment challenges - Single participant discontinued after placebo, no relevant outcome measure data was recorded.) | ||
| Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years[NCT00230893] | 99 participants | Observational | 2005-07-31 | Completed | |||
| Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade[NCT00233467] | 0 participants (Actual) | Observational | 2005-09-01 | Withdrawn (stopped due to Funding expired; no subjects enrolled as this was a retrospective chart review) | |||
| Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD[NCT00133822] | Phase 1/Phase 2 | 65 participants | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"PCL-C (post traumatic check list for civilians) is a measure of the severity of post traumatic stress disorder (PTSD), and can also be used for screening populations, It is a self-completed questionnaire with 17 questions scoring from 1 - 5. The scores of each question are added to create the total score for each participant. The highest possible score for any individual is 85, the lowest score being 17. A diagnostic score for PTSD is accepted as being more than 50. Participants completed the PCL-C just before treatment and one week later. The wait list group received no treatment at Time 1.~In the treatment arm, measure immediately pre-treatment (baseline) (time 1) and one week later (time 2).~In the wait-list no therapy arm, measure at baseline (time 1), and after one week (no treatment) (time 2). The wait-list group (Thought Field Therapy group) were then treated and reassessed after a further week (time 3)." (NCT01681628)
Timeframe: Baseline (Time 1), One week later (Time 2) and Two weeks later (Time 3 for Wait-list: Thought field Therapy Arm)
| Intervention | units on a scale (Mean) |
|---|---|
| Thought Field Therapy | 32.4 |
| Wait List: no Therapy | 12.4 |
| Wait-list: Thought Field Therapy | 20.6 |
PCL-C (post traumatic check list for civilians) is a measure of the severity of post traumatic stress disorder (PTSD), and can also be used for screening populations, It is a self-completed questionnaire with 17 questions scoring from 1 - 5. The scores of each question are added to create the total score for each participant. The highest possible score for any individual is 85, the lowest score being 17. A diagnostic score for PTSD is accepted as being more than 50. Participants completed the PCL-C one week following treatment and nineteen months later. Comparison of PCL-C scores at nineteen months compared to one week following treatment. (NCT01681628)
Timeframe: 1 week post-treatment (Time 2, TFT; Time 3, WL) and 19 months later.
| Intervention | units on a scale (PCL-C score) (Mean) | |
|---|---|---|
| one week following treatment | 19 months later | |
| Thought Field Therapy | 25.8 | 43.6 |
PCL-C (post traumatic check list for civilians) is a measure of the severity of post traumatic stress disorder (PTSD), and can also be used for screening populations, It is a self-completed questionnaire with 17 questions scoring from 1 - 5. The scores of each question are added to create the total score for each participant. The highest possible score for any individual is 85, the lowest score being 17. A diagnostic score for PTSD is accepted as being more than 50. Participants completed the PCL-C just before treatment and one week later. Only the wait-list control group was used as the treatment group did not not have a run-in score, and would have given inappropriately positive results. (NCT01681628)
Timeframe: Time 2 and 19 months later.
| Intervention | percentage of PCL-C scores >50. (Number) | |
|---|---|---|
| PCL-C score pre-treatment (time 2) >50 | % with PCL-C score >50 at 19 months | |
| Wait List Group | 41.8 | 26.6 |
PCL-C (post traumatic check list for civilians) is a measure of the severity of post traumatic stress disorder (PTSD), and can also be used for screening populations, It is a self-completed questionnaire with 17 questions scoring from 1 - 5. The scores of each question are added to create the total score for each participant. The highest possible score for any individual is 85, the lowest score being 17. A diagnostic score for PTSD is accepted as being more than 50. Participants completed the PCL-C just before treatment and one week later. The wait list group received no treatment at Time 1. (NCT01681628)
Timeframe: Baseline (Time 1), One week later (Time 2) and Two weeks later (Time 3 for Wait-list: Thought field Therapy Arm)
| Intervention | percentage with PCL-C score > 50 (Number) | |
|---|---|---|
| Time 1 | Time 2 | |
| Thought Field Therapy | 67.5 | 1.8 |
| Wait List no Treatment | 82.8 | 41.8 |
PCL-C (post traumatic check list for civilians) is a measure of the severity of post traumatic stress disorder (PTSD), and can also be used for screening populations, It is a self-completed questionnaire with 17 questions scoring from 1 - 5. The scores of each question are added to create the total score for each participant. The highest possible score for any individual is 85, the lowest score being 17. A diagnostic score for PTSD is accepted as being more than 50. Participants completed the PCL-C just before treatment and one week later. The wait list group received no treatment at Time 1. (NCT01681628)
Timeframe: Baseline (Time 1), One week later (Time 2) and Two weeks later (Time 3 for Wait-list: Thought field Therapy Arm)
| Intervention | percentage with PCL-C score > 50 (Number) | |
|---|---|---|
| Time 2 | Time 3 | |
| Wait List: Thought Field Therapy | 41.8 | 1.9 |
The primary outcome measure for this study was the total score on the 34-item Clinician-Administered PTSD Scale (CAPS). This study was the intent-to-treat analysis of the improvement in PTSD symptoms from baseline to week-24 follow-up as measured by the CAPS. Total score range for the CAPS is 0-136 with higher values representing a worse outcome. This study was powered initially to detect a 9-point difference between the treatment groups in the CAPS change score. (NCT00099983)
Timeframe: 24 Weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Risperidone | -16.3 |
| Sugar Pill | -12.5 |
"Intensity of Suicidal Ideation was monitored over the course of the trial by the second section of the Columbia Suicide Severity Rating Scale (CSSRS). This section is only administered if the patient answers yes to the first section. The section consists of 5 questions that refer to the most severe level of ideation endorsed in the first section of the CSSRS. The total score ranges from 2 to 25, with a higher number indicating more intense ideation and greater risk.~Only lifetime intensity of suicidal ideation was explored as the patient had no suicidal ideation from the month prior to beginning the study to the completion of the study" (NCT01917318)
Timeframe: Baseline
| Intervention | score on a scale (Number) |
|---|---|
| Placebo / Iloperidone | 16 |
Aggression was measured by the Modified Overt Aggression Scale (MOAS).This assessment measures four types of aggressive behavior (verbal, aggression against property, autoaggression, and physical aggression) . Total scores on the MOAS range from 0-40, with a higher score indicating more aggressive behavior. (NCT01917318)
Timeframe: Randomization and 8 weeks of treatment, during both treatment periods
| Intervention | units on a scale (Number) | |||
|---|---|---|---|---|
| MOAS at randomization 1 | MOAS after 8 weeks with placebo | MOAS at randomization 2 | MOAS after 2 weeks with iloperidone treatment | |
| Placebo / Iloperidone | 1 | 0 | 0 | 0 |
"The Clinician-Administered PTSD Scale (CAPS) is a structured interview used to diagnose and assess PTSD. Part B of CAPS evaluates symptoms of re-experiencing. Part D evaluates avoidance and numbing.~CAPS-B scores range from 0 to 40 where higher scores indicate more symptoms. A score 0 means no re-experiencing symptoms.~CAPS-D scores range form 0 to 56 and higher scores indicate more symptoms. A score 0 means no avoidance or numbing symptoms.~The primary endpoint was changes in CAPS part B and D after 8 weeks of treatment." (NCT01917318)
Timeframe: Randomization and at the end of each treatment period. Placebo treatment lasted 8 weeks. Iloperidone treatment lasted 2 weeks.
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| CAPS part B at randomization 1 | CAPS part B after 8 weeks with placebo | CAPS part B at randomization 2 | CAPS part B after 2 weeks with iloperidone | CAPS part D at randomization 1 | CAPS part D after 8 weeks with placebo | CAPS part D at randomization 2 | CAPS part D after 2 weeks with iloperidone | |
| Placebo / Iloperidone | 20 | 4 | 4 | 0 | 6 | 2 | 7 | 0 |
The presence and severity os suicidal behavior was monitored over the course of the trial by the third section of the Columbia Suicide Severity Rating Scale (CSSRS). This sections consists of questions about 5 suicidal behaviors and non-suicidal self injurious behavior and it can be answered yes or no. The number of participants who experienced suicidal behavior is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal behavior | 1 month prior ro screening | During the course of the study | |
| Placebo / Iloperidone | 0 | 0 | 0 |
The presence of suicidal ideation was monitored over the course of the trial by the first section of the Columbia Suicide Severity Rating Scale (CSSRS). This first section of the scale consists of 5 questions that can be answered yes or no. The number of participants who reported experiencing suicidal ideation is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal ideation | 1 month prior to screening | Suicidal ideation during the study | |
| Placebo / Iloperidone | 1 | 0 | 0 |
5 reviews available for risperidone and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
Meta-analysis of the efficacy of treatments for posttraumatic stress disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Fructose; Humans; Male; Psycho | 2013 |
A review of atypical antipsychotic medications for posttraumatic stress disorder.
Topics: Antipsychotic Agents; Controlled Clinical Trials as Topic; Dibenzothiazepines; Humans; Quetiapine Fu | 2011 |
Creating more effective antidepressants: clues from the clinic.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dep | 2006 |
The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials.
Topics: Antipsychotic Agents; Benzodiazepines; Data Interpretation, Statistical; Double-Blind Method; Humans | 2008 |
[Antipsychotics, anticonvulsants, antiadrenergics and other drugs: what to do when posttraumatic stress disorder does not respond to selective serotonin reuptake inhibitors?].
Topics: Adrenergic Antagonists; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Humans; Lamotrigine; | 2007 |
11 trials available for risperidone and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Impact of multi-site clinical trial results on clinical practice: Use of risperidone to treat PTSD nationally in the veterans health administration.
Topics: Antipsychotic Agents; Humans; Risperidone; Stress Disorders, Post-Traumatic; United States; United S | 2023 |
Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Combat Disorders; Diagnosis, | 2014 |
Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504.
Topics: Adult; Aged; Combat Disorders; Double-Blind Method; Female; Humans; Interview, Psychological; Male; | 2016 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms.
Topics: Adult; Antipsychotic Agents; Comorbidity; Double-Blind Method; Humans; Male; Middle Aged; Military P | 2003 |
Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder.
Topics: Aggression; Antipsychotic Agents; Double-Blind Method; Humans; Irritable Mood; Middle Aged; Psychiat | 2003 |
A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Child; Child Abuse; Child Abuse, Sexual; D | 2004 |
Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Evaluation; Follow-Up Studies; Humans; Male; | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women.
Topics: Adult; Aged; Antipsychotic Agents; Domestic Violence; Double-Blind Method; Female; Humans; Middle Ag | 2006 |
Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Demography; Diagnostic and Statistical Manual of Ment | 2008 |
16 other studies available for risperidone and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Co-treatment of piracetam with risperidone rescued extinction deficits in experimental paradigms of post-traumatic stress disorder by restoring the physiological alterations in cortex and hippocampus.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Corticosterone; Disease Models, Animal; Drug Synerg | 2019 |
A case series of shared delusional infestation: folie à deux revisited.
Topics: Adult; Antipsychotic Agents; Delusional Parasitosis; Female; History, 19th Century; Humans; Male; Mi | 2020 |
Correlates of Nonimprovement to Pharmacotherapy for Chronic, Antidepressant-Resistant, Military Service-Related Posttraumatic Stress Disorder: Insights From the Veterans Affairs Cooperative Study No. 504.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Drug Therapy, Combination; Female; Humans; | 2017 |
Risperidone ameliorates post-traumatic stress disorder-like symptoms in modified stress re-stress model.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brain; Corticosterone; Dise | 2013 |
Review: psychotherapy, somatic therapy and pharmacotherapy are all more effective than control for the treatment of PTSD.
Topics: Antidepressive Agents; Female; Fructose; Humans; Male; Psychotherapy; Risperidone; Stress Disorders, | 2014 |
Elucidating the transdiagnostic dimensional structure of trauma-related psychopathology: Findings from VA cooperative study 504 - risperidone treatment for military service related chronic post traumatic stress disorder.
Topics: Adult; Aged; Antipsychotic Agents; Arousal; Comorbidity; Depressive Disorder, Major; Factor Analysis | 2015 |
Risperidone Attenuates Modified Stress-Re-stress Paradigm-Induced Mitochondrial Dysfunction and Apoptosis in Rats Exhibiting Post-traumatic Stress Disorder-Like Symptoms.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Apoptosis; Brain; Corticost | 2015 |
Risperidone treatment of an adolescent with severe posttraumatic stress disorder.
Topics: Adolescent; Antipsychotic Agents; Child Abuse; Child Abuse, Sexual; Dose-Response Relationship, Drug | 2009 |
Effectiveness of risperidone for the treatment of nightmares in veterans with posttraumatic stress disorder.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Combat Disorders; Dreams; Female; Humans; Male | 2010 |
Risperidone for post-traumatic combat nightmares: a report of four cases.
Topics: Adult; Aged; Antipsychotic Agents; Combat Disorders; Dreams; Humans; Male; Middle Aged; Risperidone; | 2011 |
Oral candidiasis secondary to adverse anticholinergic effects of psychotropic medications.
Topics: Antipsychotic Agents; Benztropine; Candidiasis, Oral; Child; Drug Therapy, Combination; Dyskinesia, | 2007 |
Risperidone and tardive dyskinesia.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Depressive Disorder | 1996 |
Risperidone in PTSD.
Topics: Adult; Antipsychotic Agents; Humans; Male; Middle Aged; Risperidone; Stress Disorders, Post-Traumati | 1998 |
Risperdal and parkinsonian tremor.
Topics: Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorde | 1999 |
Risperidone as an adjunct therapy for post-traumatic stress disorder.
Topics: Adult; Antipsychotic Agents; Arousal; Delusions; Female; Hallucinations; Humans; Military Personnel; | 1999 |
Risperidone in the treatment of acute stress disorder in physically traumatized in-patients.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Arm Injuries; Female; Foot Injuries; Humans; Male; | 2000 |